Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA)
originally understood to be limited to renal and hematopoietic involvement. Whereas …

Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune
haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the underlying …

Atypical hemolytic uremic syndrome (aHUS) is frequently associated in humans with loss-of-
function mutations in complement-regulating proteins or gain-of-function mutations in …

Atypical hemolytic uremic syndrome (aHUS) is characterized by thrombocytopenia,
microangiopathic hemolytic anemia, and acute kidney injury (AKI) which frequently …

In the last 10 years the knowledge of the pathophysiology of atypical hemolytic uremic
syndrome (aHUS) has substantially increased. Nevertheless, aHUS remains a severe …

Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening, chronic disease
that can affect patients of all ages. aHUS is caused by uncontrolled complement activation …

Background: The management of atypical hemolytic uremic syndrome (aHUS) has evolved
into better control of thrombotic microangiopathy (TMA) and recovery of renal functions since …

Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical hemolytic anemia,
thrombocytopenia and renal impairment. Atypical HUS (aHUS) defines non Shiga-toxin …

Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease
characterized by uncontrolled complement activation, systemic thrombotic microangiopathy …

Ravulizumab is a long-acting C5 inhibitor engineered from eculizumab with increased
elimination half-life, allowing an extended dosing interval from two to eight weeks. Here we …